Related Experiment Video
Updated: Aug 4, 2026
In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 15, 2013
CD8+/CD38+: immune activity and clinical significance in HCV patients with and without interferon therapy
A Perrella1, Perrella, P Conca
1Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy.
Insights
Cytotoxic T lymphocyte (CTL) response is crucial in chronic hepatitis C. CD8+/CD38+ T-cells correlate with viral load and may indicate treatment effectiveness in patients receiving interferon (IFN) therapy.
Area of Science:
- Immunology
- Hepatology
- Virology
Background:
- Cytotoxic T lymphocyte (CTL) response plays a vital role in managing chronic hepatitis C (HCV) infection.
- Activated CD8+ T-cells, identified by the CD38 marker, are key players in antiviral immunity.
- Understanding immune markers can improve treatment strategies for chronic hepatitis C.
Purpose of the Study:
- To evaluate CD8+/CD38+ T-cells as an immunophenotypic marker in chronic hepatitis C patients.
- To assess the correlation between CD8+/CD38+ T-cells, viral load (HCV-RNA), and ALT levels.
- To investigate the potential role of CD8+/CD38+ T-cells during interferon (IFN) therapy.
Main Methods:
- A cohort of 22 chronic hepatitis C patients was studied over four months.
- Patients were divided into two groups: one receiving IFN therapy (Group A) and a control group (Group B).
- Flow cytometry was used to analyze CD8+/CD38+ T-cell populations; ALT levels and HCV-RNA were monitored.
Main Results:
- Interferon (IFN) therapy led to a significant reduction in ALT levels (p < .05).
- A strong positive correlation was observed between CD8+/CD38+ T-cells and HCV-RNA levels (r = .894; p < .05).
- IFN therapy appeared to enhance CD8+/CD38+ T-cell activity, potentially by increasing MHC I expression.
Conclusions:
- The CD8+/CD38+ T-cell marker may serve as a valuable indicator of viral activity in HCV patients.
- This marker could also reflect the immunological status during IFN treatment.
- CD8+/CD38+ T-cells might contribute to controlling viral replication and reducing liver inflammation in chronic hepatitis C.
Abstract:
At the light of the importance of cytotoxic T lymphocyte (CTL) response during chronic hepatitis C, we carried out a study in order to evaluate the CD8+/CD38+T-cells, immunophenotypic marker of CD8+ activated cells in a selected cohort of 22 patients for four months. The patients were subdivided in two groups: A (with IFN therapy), B (without IFN therapy). The results show that in IFN-treated subjects there is a significant reduction of ALT (sign test, z = .424;p < or = .05) and that the CD8+/CD38+ present a positive correlation with HCV-RNA (r = .894; p < .05). We hypothesize that during IFN therapy the CD8+/CD38+ activity is able to oppose HCV, probably by increasing MHC I expression on the infected cells due to the IFN modulatory action, that could strengthen the immune response of CD8+ activated T-lymphocytes. These events confer the capacity to specifically respond to any viral replication and probably take part in the reduction of ALT levels by decreasing the chronic inflammation present during a defective immune response. These data show think CD8+/CD38+ marker could be a good parameter to evaluate both the viral activity and immunological status in HCV+ patients undergoing IFN treatment.
